In intensive care medicine, various plasma proteins from Biotest are already in use today, for instance as volume and protein replacement in severe injuries and burns and also for the treatment of severe bacterial infections (e.g. sepsis).
Continuing this practice, Biotest is developing the polyvalent antibody preparation Trimodulin, which contains relevant amounts of IgM and IgA antibodies in addition to IgG, for the treatment of patients with severe community-acquired pneumonia (sCAP) and patients with severe COVID-19.
Moreover, we have developed an innovative fibrinogen concentrate, used amongst others to treat life-threatening bleedings, approved by EMA and FDA.
